Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Testosterone Cypionate. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AR known ✓ | P10275 | 5/20 | 0.76 |
| ▸ | CYP3A4 | P08684 | 8/20 | 0.76 |
| ▸ | LMNA | P02545 | 8/20 | 0.76 |
| ▸ | TSHR | P16473 | 5/20 | 0.76 |
| ▸ | MAPT | P10636 | 5/20 | 0.76 |
| ▸ | PGR | P06401 | 5/20 | 0.76 |
| ▸ | NR3C1 | P04150 | 4/20 | 0.76 |
| ▸ | NR1I2 | O75469 | 3/20 | 0.76 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.76 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.76 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.76 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.76 |
| ▸ | CYP19A1 | P11511 | 4/20 | 0.75 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.58 |
| ▸ | SHBG | P04278 | 4/20 | 0.58 |
| ▸ | SERPINA6 | P08185 | 4/20 | 0.58 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.58 |
| ▸ | GPBAR1 | Q8TDU6 | 3/20 | 0.58 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | SNCA | P37840 | 2/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Testosterone Cypionate SCHEMBL1170689 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNATSHRMAPTPGR | |
| Testosterone Cypionate SCHEMBL40862 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNATSHRMAPTPGR | |
| Testosterone Cypionate SCHEMBL16210495 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNATSHRMAPTPGR | |
| Testosterone Cypionate SCHEMBL18078434 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNATSHRMAPTPGR | |
| Testosterone Cypionate SCHEMBL26224948 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNATSHRMAPTPGR | |
| Testosterone Cypionate SCHEMBL5021654 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNATSHRMAPTPGR | |
| Testosterone Cypionate SCHEMBL12754434 | 1.00 | CYP3A4 (0.76) | CYP3A4LMNATSHRMAPTPGR | |
| Testosterone Cypionate SCHEMBL10432170 | 0.99 | CYP3A4 (0.75) | CYP3A4LMNATSHRMAPTPGR | |
| Testosterone Cypionate SCHEMBL5697113 | 0.99 | CYP3A4 (0.75) | CYP3A4LMNATSHRMAPTPGR | |
| SCHEMBL5664755 | 0.99 | CYP3A4 (0.75) | CYP3A4LMNATSHRMAPTPGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230248720-A1 | Long Acting Injectable Formulations | ABON PHARMACEUTICALS, LLC | 2023-08-10 | — | — | US | disclosed |
| US-11596628-B2 | Long acting injectable formulations | ABON PHARMACEUTICALS, LLC (US) | 2023-03-07 | — | — | US | disclosed |
| EP-3400016-A1 | LONG ACTING INJECTABLE FORMULATIONS | Abon Pharmaceuticals, LLC (US) | 2018-11-14 | — | — | EP | disclosed |
| US-20170196802-A1 | Long Acting Injectable Formulations | ABON PHARMACEUTICALS, LLC (US) | 2017-07-13 | — | — | US | disclosed |
| US-20170196855-A1 | Long Acting Injectable Formulations | ABON PHARMACEUTICALS, LLC (US) | 2017-07-13 | — | — | US | disclosed |
| WO-2017119928-A1 | LONG ACTING INJECTABLE FORMULATIONS | ABON PHARMACEUTICALS, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| WO-2017119936-A1 | LONG ACTING INJECTABLE FORMULATIONS | ABON PHARMACEUTICALS, LLC (US) | 2017-07-13 | — | — | WO | disclosed |
| EP-1305029-A4 | METHOD OF INCREASING SENSITIVITY OF MAMMOGRAPHY | CLEVELAND CLINIC FOUNDATION (US) | 2005-05-04 | — | — | EP | disclosed |
| EP-1305029-A1 | METHOD OF INCREASING SENSITIVITY OF MAMMOGRAPHY | THE CLEVELAND CLINIC FOUNDATION (US) | 2003-05-02 | — | — | EP | disclosed |
| WO-2002009721-A1 | METHOD OF INCREASING SENSITIVITY OF MAMMOGRAPHY | THE CLEVELAND CLINIC FOUNDATION (US) | 2002-02-07 | — | — | WO | disclosed |